Literature DB >> 8196291

Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis?

E Maggi1, R Bellazzi, F Falaschi, A Frattoni, G Perani, G Finardi, A Gazo, M Nai, D Romanini, G Bellomo.   

Abstract

Since oxidized low-density lipoprotein (LDL) is more atherogenic than native LDL, LDL oxidation was investigated in uremic patients who often develop accelerated atherogenesis. Three groups of uremic patients were studied (10 on predialysis conservative therapy, 11 on repetitive hemodialysis, 13 on peritoneal dialysis) and compared with seventy matched controls. LDL oxidation was evaluated in all patients as: (i) the susceptibility to in vitro oxidation (by measuring the resistance to Cu(++)-induced formation of conjugated dienes), (ii) vitamin E concentration in LDL, and (iii) presence of plasma anti-oxidized LDL antibodies, expressed as the ratio anti-oxLDL/anti-nativeLDL antibodies. The lipid profile was studied in all patients. Vitamin E concentration did not differ between the various groups, although LDL from uremic patients appeared more susceptible to in vitro and in vivo oxidation (as demonstrated by an earlier generation of conjugated dienes and by the presence of an higher antibody ratio) compared to control subjects. Subclass analysis of the different patients revealed that peritoneal dialysis treatment ameliorated the oxidation markers. However, a prolonged dialytic treatment caused a decrease in vitamin E concentration in LDL and increased their susceptibility to oxidation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8196291     DOI: 10.1038/ki.1994.115

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  24 in total

1.  Immunological evidence for hypochlorite-modified proteins in human kidney.

Authors:  E Malle; C Woenckhaus; G Waeg; H Esterbauer; E F Gröne; H J Gröne
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

2.  Factors affecting resistance of low density lipoproteins to oxidation.

Authors:  O Ziouzenkova; S P Gieseg; P Ramos; H Esterbauer
Journal:  Lipids       Date:  1996-03       Impact factor: 1.880

3.  Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials.

Authors:  Min Jun; Jicheng Lv; Vlado Perkovic; Meg J Jardine
Journal:  Ther Adv Chronic Dis       Date:  2011-07       Impact factor: 5.091

4.  Impact of low-dose urokinase in peritoneal dialysis on serum oxidative stress, nitric oxide and endothelin in cerebral infarction complicated with uremia.

Authors:  Zhong-Sen Qu; Qing-De Zhang; Liang Li
Journal:  Int J Clin Exp Med       Date:  2015-01-15

5.  Dyslipidaemia and hyperlipidaemia following renal transplantation.

Authors:  L Lócsey; L Asztalos; Z Kincses; F Gyórfi; C Berczi
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

6.  Disorders of lipid metabolism and chronic kidney disease in the elderly.

Authors:  Devasmita Choudhury; Meryem Tuncel; Moshe Levi
Journal:  Semin Nephrol       Date:  2009-11       Impact factor: 5.299

7.  Oxidative stress in children on hemodialysis: value of autoantibodies against oxidized low-density lipoprotein.

Authors:  Nurcan Cengiz; Esra Baskin; Nurzen Sezgin; Pinar Agras; Mehmet Haberal
Journal:  Pediatr Nephrol       Date:  2008-10-29       Impact factor: 3.714

8.  Reduction of serum antioxidative capacity during hemodialysis.

Authors:  Keisuke Nakayama; Hiroyuki Terawaki; Masaaki Nakayama; Masashi Iwabuchi; Toshinobu Sato; Sadayoshi Ito
Journal:  Clin Exp Nephrol       Date:  2007-09-28       Impact factor: 2.801

9.  Serum Paraoxonase Levels are Correlated with Impaired Aortic Functions in Patients with Chronic Kidney Disease.

Authors:  Tolga H Efe; Ahmet G Ertem; Alpaslan Altunoglu; Cemal Koseoglu; Ali Erayman; Murat Bilgin; Özge Kurmuş; Turgay Aslan; Mehmet Bilge
Journal:  Acta Cardiol Sin       Date:  2016-01       Impact factor: 2.672

10.  Paraoxonase activity and antibodies to oxidized-LDL in chronic renal failure patients on renal replacement therapy.

Authors:  P R Krishnaswamy; Anjali Rao; W Murali; H Sudarshan Ballal
Journal:  Indian J Clin Biochem       Date:  2006-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.